Login to Your Account



Biotie Acquiring Newron in Potential $61M Share Deal

By Cormac Sheridan


Wednesday, September 28, 2011
Biotie Therapies Oyj took another step along its growth-by-acquisition pathway by agreeing to take over Newron Pharmaceuticals SpA in a stock-based deal valued at €37.4 million (US$50.7 million) initially, with another possible €7.2 million in share-based milestones on the table.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription